Reneo Pharmaceuticals, Inc.

$18.20+952.02%(+$16.47)
TickerSpark Score
63/100
Mixed
93
Valuation
20
Profitability
20
Growth
100
Health
80
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPHM research report →

52-Week Range20% of range
Low $1.68
Current $18.20
High $82.90

Companyreneopharma.com

Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.

CEO
Gregory J. Flesher
IPO
2021
Employees
8
HQ
Irvine, CA, US

Price Chart

-75.44% · this period
$84.30$48.70$13.10Oct 05Apr 08Oct 04

Valuation

Market Cap
$60.84M
P/E
0.00
P/S
0.00
P/B
1.35
EV/EBITDA
2.85
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
0.00%
ROIC
0.00%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$0 · 0.00%
EPS
$-4.40 · 0.00%
Op Income
$-62,950,000
FCF YoY
-1.38%

Performance & Tape

52W High
$82.90
52W Low
$1.68
50D MA
$14.92
200D MA
$16.09
Beta
0.22
Avg Volume
17.98K

Get TickerSpark's AI analysis on RPHM

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Sep 25, 24Leonard Braden Michaelbuy68,746
Sep 24, 24Leonard Braden Michaelbuy29,600
Sep 18, 24Leonard Braden Michaelbuy806
Sep 17, 24Leonard Braden Michaelbuy55,300
Sep 16, 24Leonard Braden Michaelbuy172,747
Sep 13, 24Leonard Braden Michaelbuy150,000
Sep 12, 24Leonard Braden Michaelbuy36,176
Aug 14, 24Leonard Braden Michaelbuy100,487
Aug 13, 24Leonard Braden Michaelbuy171,339
May 14, 24Leonard Braden Michaelbuy335,000

Our RPHM Coverage

We haven't published any research on RPHM yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate RPHM Report →

Similar Companies